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Abstract The objective of this study is to assess patient prefer-
ences for treatment-related benefits and risk of disease relapse in
the management of low disease states of psoriatic arthritis (PsA).
Focus groups with patients and a literature review were under-
taken to determine the characteristics of treatment and symptoms
of PsA important to patients. Patient preferences were assessed
using a discrete choice experiment which compared hypothetical
treatment profiles of the risk and benefits of treatment withdraw-
al. The risk outcome included increased risk of disease relapse,
while benefit outcomes included reduced sickness/nausea from
medication and changes in health-related quality of life. Each
patient completed 12 choice sets comparing treatment profiles.
Preference weights were estimated using a logic regression mod-
el, and the maximum acceptable risk in disease relapse for a
given improvement in benefit outcomes was elicited. Final sam-
ple included 136 patients. Respondents attached the greatest im-
portance to eliminating severe side effects of sickness/nausea and
the least importance to a change in risk of relapse. Respondents
were willing to accept an increase in the risk of relapse of 32.6%
in order to eliminate the side effects of sickness/nausea. For
improvements in health status, the maximum acceptable risk in
relapse was comparable to a movement from some to no
sickness/nausea. The study suggests that patients in low disease
states of PsA are willing to accept greater risks of relapse for
improvements in side effects of sickness/nausea and overall
health status, with the most important benefit attribute being the
elimination of severe sickness or nausea.
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Introduction
Psoriatic arthritis (PsA) is an inflammatory arthritis affecting
the joints and connective tissue and is associated with psoria-
sis of the skin or nails [1]. It is characterised by pain, swelling
and inflammation of the joints. Psoriasis affects 2–3 % of the
UK population, and the prevalence of inflammatory arthritis
in patients with psoriasis is estimated to be up to 30 % [2, 3].
There is currently no cure for PsA and conventional
disease-modifying anti-rheumatic drugs (DMARDs) have
shown limited efficacy in clinical trials [4]. Modest efficacy
has been shown for sulfasalazine [5] and leflunomide [6] with
conflicting evidence shown for methotrexate (MTX) [7].
However, the use of anti-tumour necrosis factor (TNF) thera-
py for the treatment of inflammatory arthritis has
revolutionised therapeutic options in PsA. TNF inhibitors
are highly effective against both skin and joints but they are
expensive and associated with potentially serious adverse
events. With the introduction of these agents, remission in
PsA is now an achievable target. However, in some clinical
situations, the risks and side effects associated with treatment
may outweigh the benefits of therapy [8]. The effects of long-
term immunosuppressant therapy are unknown. The econom-
ic impact of psoriasis is also important [9–11]. If patients
experience some degree of treatment interruption while
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remaining in remission, this would significantly reduce the
treatment costs for PsA patients.
It has recently been shown that remission in PsA may be
sustained despite treatment interruption [12]. However, two
further studies have suggested that complete withdrawal of
treatment leads to relapse in the majority of patients [13, 14].
In order for patients to make an informed decision about
whether or not to have their treatments withdrawn or scaled
down, they must be advised of both the benefits (e.g. fewer
side effects associated with treatment) and risks (e.g. risk of
relapsing after a state of remission). Patient-preference
methods such as discrete choice experiments (DCEs) [15,
16] have increasingly been used to quantify the relative im-
portance of the benefits and risks of treatment to patients [17,
18]. The primary objective of this study was to undertake a
DCE to quantify the trade-off between benefit and risk pref-
erences for patients in low disease states of PsA in order to
inform the non-inferiority margin in risk of relapse between
staying on treatment and withdrawing from treatment. This
can be achieved by asking individuals to state preferences
over particular features of treatment. Specifically, the objec-
tive was to estimate the trade-off between the primary out-
come measure of risk of relapse (flare of disease), side effects
of treatment and symptoms of PsA. The maximum acceptable
risk in negative outcomes that patients are willing to accept for
a given improvement in benefit outcomes represents the level
of non-inferiority from the patients’ perspective. If a future
randomised control trial (RCT) were to be planned
based on patient preferences, this elicited non-inferiority mar-
gin could be used in a standard sample size and power calcu-
lation to determine the sample size required for a full non-
inferiority RCT.
Methods
Review of literature
A literature review was conducted to determine the set of
characteristics or attributes (e.g. symptoms of PsA, side effects
of treatment) important to patients. However, in the initial
stages of reviewing the literature, it became clear that ‘tradi-
tional’ systematic searching methods using keywords was not
possible. This was because identifying the key terms and
Medical Subject Headings (MeSH) that capture the range of
relevant literature is difficult without having pre-existing
knowledge of the important characteristics or attributes to be
determined. Therefore, a ‘pearl growing’ technique was used
to identify the relevant literature. This approach uses a pool of
‘initial pearls’ identified by experts in the field of rheumatol-
ogy and experienced in the treatment of PsA (PH, LC, AC) to
grow the literature through references and/or citations until all
relevant studies have been identified. Repetition of the pearl
growing process was continued up to the point that it was felt
that no additional information from the literature could be
obtained. Details on symptoms of PsA and treatment charac-
teristics, particularly adverse effects, were extracted from
these ‘pearls’. A hand-searching approach was used to extract
the themes from these studies. We first identified a provisional
list based on the first study examined and then subsequently
updated the list as further studies from the identified sample
were reviewed. The Summary of Product Characteristics
(SPC) was used as an additional source of information
for obtaining the adverse effects associated with medi-
cations for PsA.
Twenty-one studies were initially identified. From these, a
further 464 studies were identified through reference
searching, of which 343 were excluded as not relevant to the
topic. Titles and abstracts of the remaining 142 studies were
screened for inclusion. Of these, full copies of 74 studies were
retrieved and reviewed in order to identify the characteristics
of treatment important to patients. None of the studies were
specifically designed to examine the attributes of treatment.
Most of the studies considered outcome or disease activity
measures, efficacy and safety of treatments, burden of disease,
benefits of therapy and/or potential factors to predict remis-
sion and sustained minimal disease activity. However, within
these studies, a number of important characteristics were iden-
tified: (i) ability to work and time lost fromwork; (ii) ability to
undertake household tasks and activities at home; (iii) partic-
ipation in social activities; (iv) patient time spent caring for
PsA; (v) frequency of hospital inpatient stays, outpatient ap-
pointments and out-of-pocket expenses; and (vi) anxiety,
stress, depression, pain, fatigue and sleep disturbance. The
major adverse effects associated with treatment were identi-
fied as follows: (i) nausea, sickness, fatigue, headache, diar-
rhoea; (ii) infections and allergic reactions; (iii) abdominal and
musculoskeletal pain; (iv) hair loss; (v) need for regular blood
tests; and (vi) implications for pregnancy.
Focus groups
Focus groups with PsA patients were used to refine and ex-
pand upon the treatment characteristics revealed by the litera-
ture into a set of attributes and levels to be used in the design
of the DCE. The focus groups encouraged patients to discuss
the symptoms of PsA, the side effects of medication and the
potential consequences of stopping treatment (in particular,
the risk of relapse). They were also used to provide a guide
to the range of relapse rates that patients might be willing to
accept. Patients with a wide spectrum of disease characteris-
tics presenting for routine rheumatology appointments at St
Luke’s Hospital, Bradford UK participated in two separate
focus groups of 12 and 6 participants; the discussions were
structured by an expert in qualitative analysis/focus groups
and each session lasted approximately 1 h 30 min. Patient
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consent was obtained according to the Declaration of Helsinki
and the study was approved by the National Health Service
(NHS) Research Ethics Committee (REC) in UK.
Participants discussed how PsA affects their usual activi-
ties, work and ability to interact with friends and family due to
pain, fatigue and swelling. They also discussed how medica-
tion eases the symptoms of PsA and generally allows them to
lead a fairly normal life. Flares of disease happen quite often
but less so on medication. Some participants expressed con-
cern about the long-term consequences of taking medication.
Side effects while on medication were particularly noted for
methotrexate, which can cause nausea, vomiting and diar-
rhoea. The majority of participants did not want to come off
their current medication because of the risk of relapse and the
time required for medication to become effective again after a
break. Participants indicated that the side effects of treatment
were not sufficiently bad to consider treatment withdrawal.
However, some participants would consider the possibility
of treatment withdrawal due to concerns about the long-term
consequences of treatment and possible toxicities. Some par-
ticipants indicated that they had stopped medication pre-
viously and noted that it was good not to experience the
side effects of treatment; however, symptoms of PsA
generally returned later.
Discrete choice experiment
To inform the feasibility of a future trial of treatment with-
drawal, the willingness of patients to withdraw from treatment
needs to be determined. A DCE was used to quantify the
trade-off between benefits of medication and risk of relapse
for patients in low disease states of PsA. The attributes in the
DCE were used to represent the characteristics of treatment
and symptoms of PsA important to patients, while the levels
represent the values that these attributes may take. The attri-
butes and levels identified by the literature review were sup-
plemented by the focus group information using a thematic
approach. This was done by group consensus and with input
from a patient representative. The final set of attributes and
levels were chosen to minimise the number of possible levels
(for cognitive as well as computational ease) and reduce any
overlap between attributes.
The dimensions of the EQ-5D [19, 20] were found to fit the
symptoms of PsAvery well. These were used to represent five
of the attributes: mobility, self-care, usual activities, pain or
discomfort and anxiety or depression. The use of the EQ-5D
dimensions to represent the symptoms of PsA has the added
advantage that health-related quality of life utility values are
available (i.e. values that reflect an individual’s preference for
different health outcomes, which are measured on an interval
scale with zero reflecting states of health equivalent to death
and one reflecting perfect health). A further two attributes
were added, one to represent the risk of relapse (most often
described as a flare) and one to represent the side effects of
treatment, specifically sickness and nausea. The range of
levels for each attribute were chosen to represent the
boundaries of PsA health and the maximum range over
which respondents would be willing to accept trade-offs
among attributes.
Once attributes and levels were determined, they were
combined into treatment profiles that describe hypothetical
scenarios. In defining the choice sets, consideration was given
to the cognitive burden on respondents; for example, a full
factorial design representing the full range of combinations
of seven attributes with three levels each would result in
37 = 2187 possible health outcome profiles. To reduce the
cognitive burden, the clinical team (AC, LC, PH) selected
the attributes most relevant to patients who would be consid-
ered for treatment withdrawal in PsA, i.e. patients in stable
low disease activity. Three health states were selected from the
EQ-5D: (i) Level 11111 with utility 1.0 (i.e. perfect health); (ii)
Level 11221 with utility 0.760; and (iii) Level 11222 with
utility 0.689; representing a clear ranking in severity of symp-
toms, i.e. (i) is better than (ii), which in turn is better than (iii)
in terms of health-related quality of life. Table 1 shows the
final set of attributes and levels used in the experimental de-
sign of the DCE.
In a DCE, every respondent makes a discrete choice
between alternative A or alternative B, where each al-
ternative represents a bundle of attributes at different
levels. In each choice, the rational respondent will
choose the option that yields the highest level of utility
or benefit, i.e. an individual will choose A over B if
UA(CA, S) > UB(CB, S), where U(.) is the utility de-
rived from the choice, CA and CB are the combination
of attributes and levels associated with option A and B,
respectively, and S represents the characteristics of the
individual that influences their preference. A fractional
factorial design for the DCE was used to estimate the
trade-offs as efficiently as possible [15]. The best exper-
imental design based on 12 choice sets was derived (by
ensuring level balance, orthogonality, minimal overlap
and utility balance in the choice sets [21–24]. In order
to check for ‘rational’ responses, the design also includ-
ed three choice sets with a dominated answer, i.e. one
of the pairwise options had worse levels in all attributes
than the alternative choice. A warm-up choice set, using
the same format as the actual choice sets, and introduc-
tory text explaining the objectives of the survey were
included. The questionnaire was piloted with the patient
representative on the project and two patients attending
clinic. The purpose of the pilot was to establish whether
the respondents understood the choice sets, whether the
attributes were traded, whether one attribute dominated
the others and whether the responses were internally
consistent. The final version of the survey was sent
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for ethics approval and mailed to 644 PsA patients con-
sidered to have minimal disease activity (as defined by
Coates et al. 2010 [21]) on the Bradford Psoriatic
Arthritis Disease Register. A copy of the DCE is pre-
sented in the Supplementary Appendix.
Statistical analysis
The patterns of respondent choice was analysed using
a conditional logic regression model. In this model,
the dependent variable was the choice between A
and B and the explanatory variables were the levels
of the attributes, which measure the marginal utility
of changes in the characteristics, i.e. differences be-
tween the weights (coefficients of the regression mod-
el) for the explanatory variables indicate the relative
importance of movements between levels of each at-
tribute. The marginal rate of substitution or the trade-
off between attributes and levels was estimated by
dividing one coefficient by another. This was used
to estimate the maximum acceptable risk (MAR) in
relapse that respondents were willing to accept (i.e.
the mean level of risk in negative outcomes) for a
given improvement in benefit outcomes. It was calcu-
lated as the change in risk of relapse that would
exactly offset the perceived benefit of an improve-
ment in sickness/nausea or health status. Therefore,
the MAR represents the level of non-inferiority in
the risk of relapse from the patients’ perspective.
Results
Patient sample characteristics
Of the 644 patients who were sent the questionnaire, 247
(38 %) completed and returned it. Table 2 shows the charac-
teristics of respondents who participated in the DCE. Gender
balance was similar across participants, who were of an aver-
age age of 55 years and with PsA for an average of 8.6 years.
The majority of participants considered their PsA to be con-
trolled (64.8 %), and most were receiving treatment with ei-
ther methotrexate alone or in combination with other
DMARDs or biologics (58.7 %). A sizeable proportion of
participants (23.9 %) rated their own health as severely im-
paired with an EQ-5D utility value of less than 0.5, where a
value of 1.0 represents full health.
An unexpectedly large proportion of the responses to the
DCE (45 %) gave an ‘irrational’ answer to at least one of the
three choice sets which had a dominated answer, i.e. the
Table 1 Attributes and levels used in the DCE
Levels
1. Health-related quality of life 1. No problems with mobility, self-care, usual activities, pain or 
discomfort, anxiety or depression
2. No problems with mobility, self-care, anxiety or depression
Some problems with performing usual activities and moderate pain 
or discomfort
3. No problems with mobility or self-care
Some problems with performing usual activities
Moderate pain or discomfort, and moderate anxiety or depression
2. Risk of relapse 1. 10% chance of flare 
2. 30% chance of flare 
3. 50% chance of flare 
3. Side effects of nausea or 
sickness from treatment 
1. No nausea or sickness
2. Some nausea or sickness
3. Severe nausea or sickness
Attribute labels
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respondent did not choose the option that clearly yielded the
highest level of benefit. The reasons for this are unclear; these
participants may not have been paying close attention to the
alternative choice sets, may have misunderstood the nature of
the exercise or may have ‘perverse’ preferences. Consequently,
their responses were excluded from the sample.1 The final par-
ticipant sample size which answered all three choice sets with a
dominated answer correctly was 136.
Importance weights
Figure 1 shows the estimated weights and 95 % confidence
intervals (CIs) for the attributes and levels. Differences
between adjacent weights for attribute levels indicate the rel-
ative importance ofmoving from one level to an adjacent level
of the attribute, i.e. the greater the difference the more impor-
tant the change from one level to the next. Where the confi-
dence intervals do not overlap for adjacent levels in a partic-
ular attribute, the mean estimates are statistically different
from each other at the 5 % level of significance. Figure 1
indicates that respondents attached greater importance, by an
order of magnitude of double, of moving from severe side
effects of nausea and sickness to some nausea/sickness
(weight, 1.8668) than to moving from some to no nausea/
sickness (weight, 0.7996). The relative importance of moving
from a relapse risk of 50 % to a reduced risk of 30 % (weight,
0.4906) was similar to the movement from 30 to 10 % risk of
relapse (weight, 0.4726). For health status, slightly more im-
portance was attached to the movement from health state 2
with ‘some problems with usual activities, moderate pain and
discomfort’ to health state 1 with no problems in these dimen-
sions (weight, 0.9463) than the movement from health state 3,
which additionally had ‘moderate anxiety and depression’ to
health state 2 (weight, 0.7373). None of the confidence
intervals for the adjacent levels of any attribute over-
lapped suggesting that the levels were statistically dif-
ferent from one another.
The difference between adjacent weights of one attribute
can be comparedwith the difference between adjacent weights
of a different attribute to understand how comparable the mag-
nitude of the change is across attributes. For example, the
distance between weights for the best and worst levels of an
attribute can indicate the relative importance of one attribute to
any other attribute. Figure 2 shows the relative importance of
the attributes scaled such that the most important attribute had
a mean importance score of 1.0. It indicates that respondents
attached the greatest importance to eliminating severe side
effects of nausea and sickness and the least importance to
the change in relapse risk.
Trade-off between attributes and levels
Table 3 presents the maximum acceptable level of risk of
relapse that respondents were willing to accept in exchange
for improvements in levels of sickness/ nausea and health
status. The MAR was based on the importance of reducing
the relapse risk from 50 to 30 %. For example, the difference
in the weight between the levels of 50 and 30% risk of relapse
in Fig. 1 is 0.4906. Therefore, each percentage point increase
in risk decreases utility by 0.4906/(50−30 %) = 0.0245. The
difference in weight between the levels of the other
attributes was then measured on the same scale in order
to determine the relative trade-off between attributes.
For example, the difference in the weight between
‘some’ and ‘no’ sickness/nausea in Fig. 1 is 0.7997,
which equates to 0.7997/0.0245 = 32.6 % increase in
1 A sensitivity analysis was conducted on the full sample of 247 respon-
dents. The results were very similar for movements between the levels of
side effects of sickness/nausea and quite similar for relapse risk. However,
the results were very different for movements between levels of health
status. Given the irrational nature of the additional 111 responses, it is
difficult to interpret this finding.
Table 2 Characteristics of respondents participating in the DCE
Patient characteristics Number of
patients
(% of total)
Gender
Male
Female
115 (46.6 %)
132 (53.4 %)
Age (average age,
55 years)
<55 years old
≥55 years old
107 (43.3 %)
139 (56.3 %)
PsA controlled (from the
patients’ perspective)
Yes
No
Missing
160 (64.8 %)
76 (30.8 %)
11 (4.4 %)
Duration of PsA (average
8.6 years)
<9 years
≥9 years
Missing
141 (57.0 %)
78 (31.6 %)
28 (11.4 %)
Medication
Methotrexate alone
Other DMARDs alone
Biologics alone
Methotrexate in combination
with other DMARDs or biologics
Other DMARDs in combination
with biologics (no methotrexate)
No medication
77 (31.2 %)
38 (15.4 %)
30 (12.2 %)
68 (27.5 %)
8 (3.2 %)
26 (10.5 %)
EQ-5D utility
<0.000
0.000– <0.500
0.500– <0.750
0.750–1.000
31 (12.6 %)
28 (11.3 %)
106 (42.9 %)
82 (33.2 %)
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the risk of relapse, i.e. respondents, on average, were
willing to accept an increase in the risk of relapse of
32.6 % to eliminate the side effects of some sickness/
nausea. Therefore, the MAR in Table 3 represents the
change in risk of relapse which exactly offsets the per-
ceived benefit of improvements in levels of sickness/
nausea and health status. Respondents were willing to
accept a very large increase in risk (76.1 %) in ex-
change for an improvement in ‘severe’ to ‘some’ sick-
ness/nausea. For improvements in health status (health
state 3 → 2 and 2 → 1), the MAR was comparable to
each other and to ‘some to no’ sickness/nausea.
Fig. 1 Weights for the attribute levels
Fig. 2 Relative importance of the
attributes
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Discussion
This study is one of the first to quantitatively assess the factors
that influence a patient’s decision to withdraw from medica-
tion when in a low disease state of PsA. The focus group
discussions highlighted the concerns of participants about
the long-term consequences and side effects associated with
medication use and also the risk of relapse (‘flares’) if treat-
ment were withdrawn. The DCE was used to quantify the
trade-off between benefit and risk preferences for patients in
order to establish the non-inferiority margin where increased
risk in negative outcomes offset perceived benefits.
The study has two main findings. Firstly, the most impor-
tant benefit attribute was the elimination of severe side effects
of sickness and nausea. This was ranked more important than
moving from a health state with moderate pain or discomfort,
moderate anxiety or depression and some problems with
performing usual activities (no problems with mobility and
self-care) to a health state with none of these problems.
Secondly, the results suggest that patients are willing to accept
a very large increase (over 30%) in risk of relapse in exchange
for improvements in levels of sickness/nausea and health sta-
tus. These findings suggest that an assessment of the benefits
and risks of treatment for PsA is an important consideration
for making an informed choice about treatment withdrawal.
Patient preferences play a key role and future clinical trials
should consider patients’ current symptoms and their willing-
ness to accept different levels of relapse risk. To this end, the
elicited non-inferiority margin from the patient’s perspective
(along with an estimate of variability) could be used in a
standard sample size and power calculation to determine the
sample size needed for a full non-inferiority randomised con-
trolled trial (RCT). For example, Table 3 indicates that 32.6 %
is the non-inferiority margin in relapse rate between staying on
treatment and withdrawing from treatment that patients are
willing to accept in compensation for elimination of some side
effects of sickness/nausea. In this case, the design of the non-
inferiority RCT could be based on the hypothesis that treat-
ment withdrawal is inferior to continuation of therapy by the
minimum important difference of 32.6 % in the primary out-
come of risk of relapse (in exchange for elimination of some
sickness/nausea). This is analogous to designing a trial with a
sample size based on what the investigator believes to be a
clinically important difference in outcomes; the only differ-
ence here is that the level of non-inferiority is from the pa-
tients’ perspective based on their view of the relative impor-
tance of the benefits and risks used in the assessment.
However, an important caveat is that the design of an RCT
should not be totally driven by a limited number of trade-offs
(for example, in this case the trade-off is limited to the elim-
ination of some sickness/nausea, which was considered im-
portant to patients at the focus groups). Instead, the DCE
should be used to help guide the design of an RCT by provid-
ing a better understanding of patient preferences and the trade-
offs between attributes that individuals are willing to accept.
DCEs have been used widely in many areas of healthcare
to elicit patient preferences, but they have important limita-
tions. One limitation is that patients evaluate hypothetical
choice sets, which are intended to simulate real decisions;
however, the responses may not accurately reflect real behav-
iours as respondents do not experience the consequences of
their decisions. Therefore, differences can arise between stated
and actual preferences. Another important limitation is the
number of attributes that can be included. For ease of cognitive
burden and practical feasibility, DCEs can only consider a lim-
ited number of attributes and levels. In this respect, decisions
about the most important attributes to include in the DCE are
inevitable. In order to quantify the trade-off in risk of relapse
relative to the other attributes, we assumed that risks were linear
between the two levels of relapse (30 and 50 %) but risk pref-
erences between these levels may not be linear in reality.
This study had a number of other important limitations.
The response rate to the postal questionnaire was quite low
at 38 %. More substantial, however, was the unexpectedly
large proportion of the responses (45 %) which gave an irra-
tional answer to at least one of the three choice sets with a
dominated option. Given that we cannot be clear of the reason
for the irrational choices, the final sample only included par-
ticipants who correctly answered all three choice sets, which
resulted in quite a small sample size of 136. Moreover, it was
not possible to explore how different medications and patient
characteristics might affect patient preferences as any split in
the sample into subgroups would lead to very small sample
sizes for each group. The results reflect a survey population
who were mostly well in terms of arthritis (so may accept risk
of pain/flare) and had chronic disease with long duration. The
outcomes of such a survey may be different in patients with
early disease when first on therapy. We are not aware of any
other DCEs in PsA which have examined the risk of relapse
that patients are willing to accept for other characteristics.
Table 3 Maximum acceptable risk in relapse that respondents were
willing to accept for improvements in levels of sickness/nausea and health
status
Improvements in perceived benefits Maximum
acceptable risk
Improvements in side effects
Severe to some sickness/nausea
Some to no sickness/nausea
76.1 %
32.6 %
Improvements in health status
Health state 3 to health state 2
Health state 2 to health state 1
30.1 %
38.6 %
Based on the importance of reducing the relapse risk from 50 to 30 %.
Each percentage point increase in risk decreases patients’ utility by
0.4906/(50−30) = 0.0245
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There have been several studies focused on patient preferences
in rheumatoid arthritis [22–26]. A recent study by Harrison
et al. (2015) showed societal preference values for rheumatoid
arthritis [27]. In this study, participants were willing to trade a
year of life expectancy over a 10-year period to increase the
probability of benefiting from treatment, and two-thirds of a
year to reduce minor or serious side effects to the lowest level
[27]. In conclusion, this study provides insight into the benefit
and risk preferences of patients who may be considered for
withdrawal of treatment in PsA but is limited by the size of
the sample. Notwithstanding this, the study suggests that pa-
tients in low disease states of PsA are willing to accept greater
risks of relapse for improvements in side effects of sickness or
nausea and overall health status, with the most important ben-
efit attribute being the elimination of severe sickness or nausea.
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